autoimmune hepatitis final
TRANSCRIPT
Autoimmune HepatitisErmias Kacha(MD)
Autoimmune Hepatitis
Chronic hepatitis of unknown etiology
Can progress to cirrhosis Characteristics include:
presence of autoimmune antibody evidence of hepatitis elevation of serum globulins
Other names
Active chronic hepatitis or chronic active hepatitis
Chronic aggressive hepatitis Lupoid hepatitis Plasma cell hepatitis Autoimmune chronic active hepatitis
Epidemiology
First described in 1950’s Accounts for 5.6% of liver
transplants in the US Affects women more than men
(3.6:1) If untreated approximately 40% die
within 6 months 40% develop cirrhosis
Pathogenesis Unknown mechanism Triggers : presumed to be certain viruses, toxins,
drugs Oxyphenisatin,Methyldopa,Nitrofurantoin,Dicl
ofenac,Minocycline,statins Genetic predisposing factors:
HLA-DR3: early onset, severe form HLA-DR4: caucasian, late onset, better
response to steroids, higher incidence of extrahepatic manifestations
Antigenic mimicry Autoantigen - the cytochrome mono-oxygenase,
CYP2D6
Classification Type 1 Type 2 Overlap Syndromes(18%)
96%4%
80%
Classification
15%-34%
Classification
Autoimmune Extra hepatic Diseases
Type 1 AIH Thyroiditis (12%) Graves (6%) UC
16% of AIH have UC
5% of AIH have UC and PSC and PSC
Less commonly with RA, pernicious anemia, systemic sclerosis, ITP, SLE
Type 2 AIH DM1 Thyroiditis Vitiligo Autoimmune
Polyglandular disease10% have AIH
Overlap Syndromes Overlap with PBC
“Overlap” (“ AMA+ AIH”) Histologic AIH, Serologic PBC
Behaves like AIH type 1 “Autoimmune Cholangiopathy” (“AMA negative PBC )
Serologic AIH, Histologic PBC� Overlap with PSC ( “true AIH/PSC
overlap” ) Serologic AIH, Histologic AIH and PSC,
Cholangiographic PSC Suspect in IBD patients with AIH
Overlap Syndromes
Overlap with Viral Hepatitis Principle: Treat the predominant
diseases Review of AIH patients: 4% hep C + Review of Hep C patients: 28% ANA +,
11% SMA+ 10% of these are > 1:160, and rarely ANA+
and SMA+ AIH
Median ANA 1:320, SMA 1:160 60% + for both
Clinical Manifestations
Heterogeneous and fluctuating disease Asymptomatic (34%-45%)
Identified at routine testing, surgery, etc. Chronic symptoms
Fatigue, jaundice, anorexia, amenorrhea Fulminant hepatic failure
Acute, severe hepatitis
Clinical Manifestations
Diagnosis
Diagnostic Criteria for Autoimmune Hepatitis
Diagnostic Criteria for Autoimmune Hepatitis
Simplified Diagnostic Criteria for Autoimmune
Hepatitis
Histology
Plasma cell and Lymphocyte infiltration of Portal Field
Periportal Piecemeal Necrosis (aka Interface hepatitis) Sparing of Bile Ducts
Lobular Inflammation Bridging Necrosis and Cirrhosis
Histology
Interface Hepatitis
Treatment
Should be based on: Severity of symptoms Degree of elevation in transaminases
and IgG Histologic findings Potential side effects of treatment
AASLD Recommendations
Standard and Novel Therapies for
Autoimmune Hepatitis
Treatment Regimens for Adults
10% versus 44%
End Points of Treatment70% to 80%; 20 % sustained response
9%
End Points of Treatment13%
13%
Prednisone-Related Side Effects
Azathioprine-Related Side Effects
Special Populations at Risk for Drug Toxicity
Patients with Cirrhosis. Pregnant Patients Patients with Low Thiopurine
Methyltransferase Activity
Relapse After Drug Withdrawal
Recrudescence of disease activity after induction of remission and termination of therapy
Characterized by an increase in the serum AST level to more than three-fold the ULN and/or increase in the serum c-globulin level to more than 2 g/dL.
Liver Transplantation
Acute liver failure, decompensated cirrhosis with a MELD score >15, or hepatocellular carcinoma meeting criteria for transplantation
Recurrence of disease after transplant is common (30%).
Recurrent AIH should be treated with prednisone and azathioprine
Inability to normalize LFT justifies the addition of mycophenolate (2 g daily) to the regimen of corticosteroids and calcineurin inhibitor.
Liver Transplantation If inadequate in recurrent disease,
tacrolimus should be replaced with cyclosporine or the calcineurin inhibitors replaced with sirolimus
Retransplantation must be considered for patients with refractory recurrent AIH that is progressing to allograft loss.
5-year and 10-year patient survivals of approximately 75%
The prognosis of patients treated for recurrent AIH is comparable to patients transplanted for AIH who do not experience recurrence
Prognosis
Prognosis 40% of all pts with AIH develop cirrhosis 54% develop esophageal varices within 2 years Hepatocellular carcinoma occurs in 4% of
patients with type 1 AIH, and the 10-year probability of developing this neoplasm is 2.9%(ultrasonography at 6 months)
Poor prognosis if has presence of ascites or hepatic encephalopathy
13-20% of patients can have spontaneous resolution
Of patients who survive the most early and active stage of disease, approximately 41% of them develop inactive cirrhosis.
Of patients who have severe initial disease and survive the first 2 years, typically survive long term.
References Update on autoimmune hepatitis,
World J Gastroenterol March 7, 2009
Diagnosis and Treatment of Autoimmune Hepatitis ,HEPATOLOGY, August 2002
AASLD PRACTICE GUIDELINES,Diagnosis and Management of Autoimmune Hepatitis 2010
HEPATOLOGY, January 2005, Treatment Challenges and Investigational Opportunities in Autoimmune Hepatitis
References
Autoimmune Hepatitis, From Mechanisms to Therapy, HEPATOLOGY, Vol. 43, No. 2, Suppl. 1, 2006
Current concepts in autoimmune hepatitis, Annals of Hepatology 4(1) 2005: 6-24
Clinical features and management of autoimmune hepatitis, World J Gastroenterol June 7, 2008
Autoimmune Hepatitis, n engl j med 354;1 www.nejm.org january 5, 2006
References
Autoimmune Hepatitis: A Review, J Pak Med Assoc
Uptodate 17.3 Harrison, 17 th edition